Search Results 511-520 of 17909 for testosterone

  1. 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer - Mayo Clinic

    Participants must have a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L) 7. Participants must have received one prior approved ARDT ...

  2. Prostate cancer - Doctors and departments - Mayo Clinic

    Prostate cancer: Does PSA level affect prognosis? Prostate gland · Testosterone and prostate cancer · Transrectal biopsy of the prostate · Types of prostate ...

  3. Publications - Mayo Clinic

    Hepatic Adenomatosis in a Transgender Man on Gender-Affirming Testosterone Therapy. ACG Case Rep J. 2024 Sep; 11 (9):e01483 Epub 2024 Sept 11. View PubMed ...

  4. Prostate cancer - Doctors and departments - Mayo Clinic

    Prostate gland · Testosterone and prostate cancer · Transrectal biopsy of the prostate · Types of prostate cancer: Common and rare forms · What is prostate ...

  5. Prostate cancer - Doctors and departments - Mayo Clinic

    Prostate gland · SBRT for prostate cancer: How it compares to other treatments · Testosterone and prostate cancer · Transrectal biopsy of the prostate · Types ...

  6. Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer - Mayo Clinic

    ... Testosterone supplementation (3-month washout) 11. Active urinary tract infection. Subjects with an active infection who can be treated and re-tested with a ...

  7. Prostate cancer - Doctors and departments - Mayo Clinic

    Prostate gland · Testosterone and prostate cancer · Transrectal biopsy of the prostate · Types of prostate cancer: Common and rare forms · What is prostate ...

  8. Prostate cancer - Doctors and departments - Mayo Clinic

    Prostate gland · Testosterone and prostate cancer · Transrectal biopsy of the prostate · Types of prostate cancer: Common and rare forms · What is prostate ...

  9. XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer - Mayo Clinic

    ... testosterone (≤ 50 ng/dL) and be willing to continue the treatment throughout the study * Prior targeted or whole exome sequencing panel performed by CLIA ...

  10. Study of Cabozantinib Combined With Atezolizumab Vs. Second Novel Hormonal Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer - Mayo Clinic

    - Surgical or medical castration, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening - Measurable (extrapelvic soft tissue) metastatic ...